CR5936A - Peptidos opioides receptores kappa - Google Patents

Peptidos opioides receptores kappa

Info

Publication number
CR5936A
CR5936A CR5936A CR5936A CR5936A CR 5936 A CR5936 A CR 5936A CR 5936 A CR5936 A CR 5936A CR 5936 A CR5936 A CR 5936A CR 5936 A CR5936 A CR 5936A
Authority
CR
Costa Rica
Prior art keywords
kappa
receptious
opioid peptides
affinity
peptides
Prior art date
Application number
CR5936A
Other languages
English (en)
Inventor
Louis Junien Jean
J M Riviere Pierre
D Schteingart Claudio
Sueiras Diaz Javier
A Trojnar Jerzy
W Vanderah Todd
Original Assignee
Cara Therapeutics Inc Cara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cara Therapeutics Inc Cara Therapeutics Inc filed Critical Cara Therapeutics Inc Cara Therapeutics Inc
Publication of CR5936A publication Critical patent/CR5936A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se crean peptidos que exhiben una alta selectividad para el receptor opioide kappa (KOR) y una accion periferica de larga duracion sin una entrada significativa en el cerebro, los cuales son secuencias de residuos de aminoacidos de D-isomero cuatro con un termino C que es una amida mono o disubstituida. Los compuestos representativos, los cuales tienen una afinidad para los KORs de por lo menos 1.000 veces su afinidad para los receptores opioides mu y un ED50 de no mas de aproximadamente 0.5mg/kg.
CR5936A 1997-12-23 1998-12-22 Peptidos opioides receptores kappa CR5936A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/997,208 US5965701A (en) 1997-12-23 1997-12-23 Kappa receptor opioid peptides

Publications (1)

Publication Number Publication Date
CR5936A true CR5936A (es) 2006-08-18

Family

ID=25543752

Family Applications (1)

Application Number Title Priority Date Filing Date
CR5936A CR5936A (es) 1997-12-23 1998-12-22 Peptidos opioides receptores kappa

Country Status (33)

Country Link
US (1) US5965701A (es)
EP (1) EP1042359B1 (es)
JP (1) JP4275852B2 (es)
KR (1) KR100629548B1 (es)
CN (1) CN1154655C (es)
AR (1) AR014167A1 (es)
AT (1) ATE301670T1 (es)
AU (1) AU747806B2 (es)
BR (2) BR9814499B1 (es)
CA (1) CA2315878C (es)
CR (1) CR5936A (es)
CZ (1) CZ297281B6 (es)
DE (1) DE69831176T2 (es)
DK (1) DK1042359T3 (es)
EE (1) EE04440B1 (es)
ES (1) ES2247735T3 (es)
HK (1) HK1029349A1 (es)
HR (1) HRP20000415B1 (es)
HU (1) HU227640B1 (es)
IL (3) IL136742A0 (es)
MY (1) MY117542A (es)
NO (1) NO327080B1 (es)
NZ (1) NZ505183A (es)
PL (1) PL195842B1 (es)
PT (1) PT1042359E (es)
RU (1) RU2217437C2 (es)
SK (1) SK286135B6 (es)
TR (1) TR200001985T2 (es)
TW (1) TW580502B (es)
UA (1) UA68366C2 (es)
UY (1) UY25327A1 (es)
WO (1) WO1999032510A1 (es)
ZA (1) ZA9811801B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001036006A1 (en) * 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
EP1402899A4 (en) * 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
CN101027057B (zh) 2004-08-23 2017-04-12 曼金德公司 用于药物输送的二酮哌嗪盐、二酮吗啉盐或二酮二氧杂环己烷盐
DK1937219T3 (en) 2005-09-14 2016-02-15 Mannkind Corp A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
US20100029575A1 (en) * 2006-05-26 2010-02-04 Jean-Louis Junien N-Oxides of Kappa Receptor Peptides
WO2007139826A2 (en) * 2006-05-26 2007-12-06 Cara Therapeutics, Inc. Method for elevating prolactin in mammals
NZ577107A (en) 2006-11-10 2012-01-12 Cara Therapeutics Inc Synthetic peptide amide ligands of the kappa opiod receptor
US8906859B2 (en) * 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8236766B2 (en) * 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
WO2008077194A1 (en) * 2006-12-22 2008-07-03 Xenome Ltd Receptor agonists
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
KR102303092B1 (ko) * 2014-06-26 2021-09-15 마루이시세이야쿠가부시키가이샤 합성 펜타펩티드의 제조법
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10550150B2 (en) * 2015-05-11 2020-02-04 Cadila Healthcare Limited Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
EP3521301B1 (en) * 2016-09-27 2024-03-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Polyamide compound and use thereof
TWI712615B (zh) 2017-07-21 2020-12-11 大陸商四川海思科製藥有限公司 肽醯胺類化合物、其製備方法及醫藥用途
TWI717664B (zh) 2017-12-06 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 一種苯基丙醯胺類衍生物的鹽及其製備方法
KR20210010490A (ko) 2018-05-16 2021-01-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Kor 수용체 작용제의 약학적 조성물
CN114127085B (zh) * 2019-07-25 2024-08-13 西藏海思科制药有限公司 一种肽酰胺盐及其制备方法和在医药上的用途
WO2021013086A1 (zh) * 2019-07-25 2021-01-28 四川海思科制药有限公司 氘代肽酰胺类化合物及其制备方法和在医药上的用途
CN114615976A (zh) * 2019-08-07 2022-06-10 人福医药美国公司 κ阿片受体肽酰胺激动剂
JP7577265B2 (ja) 2020-06-25 2024-11-05 ヒューマンウェル ファーマシューティカル ユーエス，インコーポレイテッド 医学的障害の治療のためのペプチド
TW202317533A (zh) 2021-07-02 2023-05-01 美商雅斯治療公司 奧沙奈坦(osanetant)之固體形式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2013689B (en) * 1977-12-15 1982-03-24 Reckitt & Colmann Prod Ltd Compounds
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
US5367053A (en) * 1993-05-19 1994-11-22 Houghten Pharmaceuticals, Inc. Opioid peptide inhibitors
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides

Also Published As

Publication number Publication date
MY117542A (en) 2004-07-31
CA2315878C (en) 2010-11-16
WO1999032510A9 (en) 1999-09-23
EE200000370A (et) 2001-10-15
CN1154655C (zh) 2004-06-23
CZ297281B6 (cs) 2006-10-11
HUP0100626A2 (hu) 2001-08-28
TW580502B (en) 2004-03-21
BR9814499A (pt) 2000-10-10
WO1999032510A1 (en) 1999-07-01
PL341308A1 (en) 2001-04-09
SK9602000A3 (en) 2001-01-18
NO20003245D0 (no) 2000-06-21
HUP0100626A3 (en) 2001-12-28
UA68366C2 (en) 2004-08-16
CN1283201A (zh) 2001-02-07
HU227640B1 (en) 2011-10-28
JP2001526295A (ja) 2001-12-18
DE69831176T2 (de) 2006-04-20
ZA9811801B (en) 1999-06-22
PT1042359E (pt) 2005-11-30
ATE301670T1 (de) 2005-08-15
BRPI9814499B1 (pt) 2014-10-21
EE04440B1 (et) 2005-02-15
SK286135B6 (sk) 2008-04-07
PL195842B1 (pl) 2007-10-31
IL178471A0 (en) 2007-02-11
HRP20000415A2 (en) 2000-12-31
DE69831176D1 (de) 2005-09-15
NO327080B1 (no) 2009-04-20
JP4275852B2 (ja) 2009-06-10
IL136742A (en) 2006-12-31
RU2217437C2 (ru) 2003-11-27
BRPI9814499B8 (pt) 2021-11-09
AR014167A1 (es) 2001-02-07
AU747806B2 (en) 2002-05-23
HRP20000415B1 (en) 2004-06-30
BRPI9814499A (pt) 2000-10-10
US5965701A (en) 1999-10-12
AU1940299A (en) 1999-07-12
KR20010033450A (ko) 2001-04-25
EP1042359A1 (en) 2000-10-11
ES2247735T3 (es) 2006-03-01
TR200001985T2 (tr) 2000-11-21
IL136742A0 (en) 2001-06-14
EP1042359B1 (en) 2005-08-10
CZ20002382A3 (cs) 2000-12-13
NO20003245L (no) 2000-08-23
CA2315878A1 (en) 1999-07-01
KR100629548B1 (ko) 2006-09-27
DK1042359T3 (da) 2005-11-28
HK1029349A1 (en) 2001-03-30
BR9814499B1 (pt) 2014-10-21
NZ505183A (en) 2001-09-28
UY25327A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
CR5936A (es) Peptidos opioides receptores kappa
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
ES8205753A1 (es) Procedimiento para preparar amidas tetrapeptidas n-adamanta-nosustituidas
CA2076386A1 (en) Identification and expression of insect steroid receptor dna sequence
ATE363911T1 (de) Zyklische somatostatin-analoge mit einer hauptkette mit einer gespannten konformation
ES2173082T3 (es) Vectores retrovirales que contienen sitios de entrada del ribosoma internos.
BR9408063A (pt) Antagonistas de receptores de taquicinina que nÆo sÆo pept¡deos
ATE304020T1 (de) Parathyroidhormon-verwandthe peptidanaloge
MX10917A (es) Una resina sintetica y procedimiento para su preparacion
DK0929574T3 (da) Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
CA2284547A1 (en) Mu-opiate receptor peptides
MX9400255A (es) Analogos de peptidos opioides, metodo para su preparacion y composiciones farmaceuticas que los incluyen.
ES527542A0 (es) Un procedimiento para preparar nuevos peptidos
ATE328901T1 (de) Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins
NL300830I2 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
Jackson et al. Behavioural and anticonvulsant effects of Ca 2+ channel toxins in DBA/2 mice
IL123815A0 (en) Synthetic peptides that inhibit IL-6 activity
DE60226411D1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
ES2039318T1 (es) Metodo de preparacion de beta-aminoacidos quirales.
ES2180781T3 (es) Nuevos ligandos del receptor opiaceo mu: agonistas y antagonistas.
DE59601601D1 (de) Verfahren zur Reindarstellung von trans- und cis-4-Hydroxy-2,2,6-trimethyl-cyclohexan-1-on aus Isomerengemischen
ES2121088T3 (es) Analogos de peptidos limitados conformacionalmente como agentes antiplaquetarios.
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
HU9601737D0 (en) Use of amino cyclodextrins for the aqueus solubilisation of dibenzazepines for use as an antiepileptic agent
PL339296A1 (en) Novel stereoselective methods of obtaining gabapwenting analoques